Pregnancy outcome following first-trimester exposure to fingolimod : A collaborative ENTIS study
This prospective multicentre cohort study investigated pregnancy outcomes after fingolimod use for multiple sclerosis during pregnancy. Pregnancy outcomes of 63 fingolimod and 62 interferon-β-exposed pregnancies were compared. Rates of major congenital anomalies (MCA) were 4.8% (2/42) in the fingolimod group versus 2.3% (1/44) in the interferon-β group (odds ratio, 2.2; 95% confidence interval, 0.2-24.6). The adjusted hazard ratio for spontaneous abortion in fingolimod versus interferon-β-exposed pregnancies was 0.6 (95% confidence interval, 0.2-1.8). Further studies are needed to definitely rule out a moderately increased MCA risk after fingolimod exposure during pregnancy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Multiple sclerosis (Houndmills, Basingstoke, England) - 27(2021), 3 vom: 15. März, Seite 475-478 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pauliat, Emmanuelle [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Birth defect |
|---|
| Anmerkungen: |
Date Completed 24.09.2021 Date Revised 24.09.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/1352458520929628 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311177689 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311177689 | ||
| 003 | DE-627 | ||
| 005 | 20231225141711.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/1352458520929628 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1037.xml |
| 035 | |a (DE-627)NLM311177689 | ||
| 035 | |a (NLM)32538681 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pauliat, Emmanuelle |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pregnancy outcome following first-trimester exposure to fingolimod |b A collaborative ENTIS study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.09.2021 | ||
| 500 | |a Date Revised 24.09.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a This prospective multicentre cohort study investigated pregnancy outcomes after fingolimod use for multiple sclerosis during pregnancy. Pregnancy outcomes of 63 fingolimod and 62 interferon-β-exposed pregnancies were compared. Rates of major congenital anomalies (MCA) were 4.8% (2/42) in the fingolimod group versus 2.3% (1/44) in the interferon-β group (odds ratio, 2.2; 95% confidence interval, 0.2-24.6). The adjusted hazard ratio for spontaneous abortion in fingolimod versus interferon-β-exposed pregnancies was 0.6 (95% confidence interval, 0.2-1.8). Further studies are needed to definitely rule out a moderately increased MCA risk after fingolimod exposure during pregnancy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Fingolimod | |
| 650 | 4 | |a birth defect | |
| 650 | 4 | |a cohort study | |
| 650 | 4 | |a interferon | |
| 650 | 4 | |a multiple sclerosis | |
| 650 | 4 | |a pregnancy | |
| 650 | 7 | |a Fingolimod Hydrochloride |2 NLM | |
| 650 | 7 | |a G926EC510T |2 NLM | |
| 700 | 1 | |a Onken, Marlies |e verfasserin |4 aut | |
| 700 | 1 | |a Weber-Schoendorfer, Corinna |e verfasserin |4 aut | |
| 700 | 1 | |a Rousson, Valentin |e verfasserin |4 aut | |
| 700 | 1 | |a Addor, Marie-Claude |e verfasserin |4 aut | |
| 700 | 1 | |a Baud, David |e verfasserin |4 aut | |
| 700 | 1 | |a Théaudin, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Diav-Citrin, Orna |e verfasserin |4 aut | |
| 700 | 1 | |a Cottin, Judith |e verfasserin |4 aut | |
| 700 | 1 | |a Agusti, Antonia |e verfasserin |4 aut | |
| 700 | 1 | |a Rollason, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Kaplan, Yusuf C |e verfasserin |4 aut | |
| 700 | 1 | |a Kennedy, Debra |e verfasserin |4 aut | |
| 700 | 1 | |a Kadioglu, Mine |e verfasserin |4 aut | |
| 700 | 1 | |a Rothuizen, Laura E |e verfasserin |4 aut | |
| 700 | 1 | |a Livio, Françoise |e verfasserin |4 aut | |
| 700 | 1 | |a Buclin, Thierry |e verfasserin |4 aut | |
| 700 | 1 | |a Panchaud, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Winterfeld, Ursula |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Multiple sclerosis (Houndmills, Basingstoke, England) |d 1997 |g 27(2021), 3 vom: 15. März, Seite 475-478 |w (DE-627)NLM09012992X |x 1477-0970 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2021 |g number:3 |g day:15 |g month:03 |g pages:475-478 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/1352458520929628 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2021 |e 3 |b 15 |c 03 |h 475-478 | ||